Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An international, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy and safety of 150 mg XAV-19 infusion, in patients with moderate to severe COVID-19: the EUROXAV study

Next Previous
X
Search
Trial Profile

An international, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy and safety of 150 mg XAV-19 infusion, in patients with moderate to severe COVID-19: the EUROXAV study

Status: Suspended
Phase of Trial: Phase II/III

Latest Information Update: 25 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XAV-19 (Primary)
  • Indications COVID-19 pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms EUROXAV
  • Sponsors Xenothera

    • Most Recent Events

    • 25 Sep 2023 This trial has been discontinued in Spain.
    • 12 Sep 2023 This trial has been discontinued in Estonia, according to European Clinical Trials Database record.
    • 05 Jan 2023 According to a Xenothera media release, this trial is suspended due to low enrollment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top